Lu AE 04621

Drug Profile

Lu AE 04621

Alternative Names: Lu AE04621

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Class Antiparkinsonians
  • Mechanism of Action Dopamine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Dec 2016 Lundbeck completes a phase I trial in Parkinson's disease in USA (PO) (NCT02649608)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Denmark (PO, Liquid)
  • 01 Jan 2016 Phase-I clinical trials in Parkinson's disease in USA (PO) (NCT02649608)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top